Physician profile
Fleta Bray
NPI 1023468600
$3,985.53
in general payments reported to CMS, 2019-2025
12 companies · $14.11 in 2025
The $14.11 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $473 · 2020: $80.12 · 2021: $204 · 2022: $122 · 2023: $135 · 2024: $2,957 · 2025: $14.11.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,600 · Food and Beverage: $426 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,600.00 |
| Food and Beverage | $426.02 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $2,803.46 | 2022-2024 | Bimzelx |
| Abbvie INC. | $331.51 | 2019-2024 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $288.10 | 2021-2024 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $148.85 | 2019-2021 | |
| Allergan, INC. | $131.65 | 2019 | |
| Lilly USA, LLC | $128.37 | 2019 | |
| Arcutis Biotherapeutics, INC. | $44.82 | 2024 | Zoryve |
| Amgen INC. | $30.72 | 2023 | Otezla |
| Genzyme Corporation | $23.29 | 2019 | |
| Kyowa Kirin, INC. | $20.44 | 2019 | |
| Pfizer INC. | $20.21 | 2020 | |
| Resmed Corp | $14.11 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fleta Bray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.